ArticleWorld journal of gastrointestinal surgery2025
Computed tomography 3D reconstruction and texture analysis for evaluating the efficacy of neoadjuvant chemotherapy in advanced gastric cancer.
Article in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) remains a significant global health challenge, with high incidence and mortality rates. Neoadjuvant chemotherapy is increasingly used to improve surgical outcomes and long-term survival in advanced cases. However, individual responses to treatment vary widely, and current imaging methods often fall short in accurately predicting efficacy. Advanced imaging techniques, such as computed tomography (CT) 3D reconstruction and texture analysis, offer potential for more precise assessment of therapeutic response.
aimTo explore the application value of CT 3D reconstruction volume change rate, texture feature analysis, and visual features in assessing the efficacy of neoadjuvant chemotherapy for advanced GC.
methodsA retrospective analysis was conducted on the clinical and imaging data of 97 patients with advanced GC who received S-1 plus Oxaliplatin combined chemotherapy regimen neoadjuvant chemotherapy from January 2022 to March 2024. CT texture feature analysis was performed using MaZda software, and ITK-snap software was used to measure the tumor volume change rate before and after chemotherapy. CT visual features were also evaluated. Using postoperative pathological tumor regression grade (TRG) as the gold standard, the correlation between various indicators and chemotherapy efficacy was analyzed, and a predictive model was constructed and internally validated.
resultsThe minimum misclassification rate of texture features in venous phase CT images (7.85%) was lower than in the arterial phase (13.92%). The volume change rate in the effective chemotherapy group (75.20%) was significantly higher than in the ineffective group (41.75%). There was a strong correlation between volume change rate and TRG grade (
conclusionThe CT 3D reconstruction volume change rate can serve as a preferred quantitative indicator for evaluating the efficacy of neoadjuvant chemotherapy in GC. Combining it with a CT visual feature predictive model can further improve the accuracy of efficacy evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.